TY - JOUR
T1 - Next-generation cancer vaccine approaches
T2 - Integrating lessons learned from current successes with promising biotechnologic advances
AU - Le, Dung T.
AU - Jaffee, Elizabeth M.
PY - 2013/7/1
Y1 - 2013/7/1
N2 - With the recent approval of sipuleucel-T for metastatic castration-resistant prostate cancer and ipilimumab for metastatic melanoma, there is increasing excitement in the field of cancer immunotherapy. A large number of clinical trials are currently testing various vaccine vectors in a diverse array of cancer types. Which of these strategies will ultimately prove successful has yet to be determined. However, a better understanding of the complex interplay of tumor-specific T cells and the challenges faced at the tumor microenvironment, advances in biotechnology, and lessons learned from prior successes and failures will likely lead to approvals of other therapeutic cancer vaccines.
AB - With the recent approval of sipuleucel-T for metastatic castration-resistant prostate cancer and ipilimumab for metastatic melanoma, there is increasing excitement in the field of cancer immunotherapy. A large number of clinical trials are currently testing various vaccine vectors in a diverse array of cancer types. Which of these strategies will ultimately prove successful has yet to be determined. However, a better understanding of the complex interplay of tumor-specific T cells and the challenges faced at the tumor microenvironment, advances in biotechnology, and lessons learned from prior successes and failures will likely lead to approvals of other therapeutic cancer vaccines.
UR - http://www.scopus.com/inward/record.url?scp=84882984973&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84882984973&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2013.0099
DO - 10.6004/jnccn.2013.0099
M3 - Article
C2 - 23847215
AN - SCOPUS:84882984973
SN - 1540-1405
VL - 11
SP - 766
EP - 772
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 7
ER -